Plus Therapeutics rebrands to Cerenome, changes ticker to CNSY
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cerenome Launches as an Integrated CNS Oncology Company
July 31, 2026 8:30 AM EDTHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Companys name will become Cerenome, Inc. The Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol CNSY, effective market open on the same day.
The new name reflects the Company's de facto evolution from a therapeutics-focused organization into an integrated CNS oncology company. The Company has expanded beyond targeted radiotherapeutics because effective solutions for CNS... More
